Vor Biopharma (VOR) Set to Announce Quarterly Earnings on Monday

Vor Biopharma (NYSE:VOR) is scheduled to release its earnings data on Monday, April 29th.

Vor Biopharma (NYSE:VOR) last announced its earnings results on Wednesday, March 20th. The company reported ($0.39) EPS for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.10. On average, analysts expect Vor Biopharma to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Vor Biopharma Stock Performance

Shares of Vor Biopharma stock opened at $1.69 on Friday. The stock has a market cap of $115.29 million, a price-to-earnings ratio of -0.96 and a beta of -0.36. The stock has a 50 day moving average price of $2.01 and a 200-day moving average price of $2.11. Vor Biopharma has a one year low of $1.62 and a one year high of $5.70.

Analyst Ratings Changes

A number of research firms recently issued reports on VOR. JMP Securities restated a “market outperform” rating and set a $12.00 price objective on shares of Vor Biopharma in a report on Friday, March 22nd. Stifel Nicolaus dropped their price objective on Vor Biopharma from $15.00 to $12.00 and set a “buy” rating for the company in a report on Thursday, March 21st. Wedbush restated an “outperform” rating and set a $11.00 price objective on shares of Vor Biopharma in a report on Tuesday, April 23rd. HC Wainwright restated a “buy” rating and set a $17.50 price objective on shares of Vor Biopharma in a report on Thursday, March 21st. Finally, Oppenheimer restated an “outperform” rating and set a $15.00 price objective (down previously from $17.00) on shares of Vor Biopharma in a report on Thursday, March 21st. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $13.50.

About Vor Biopharma

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.